$BDTX
Black Diamond Therapeutics Inc

2021 Q2 Form 10-Q Financial Statement

#000170154121000034 Filed on August 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.996M $4.860M
YoY Change 64.53% 260.0%
% of Gross Profit
Research & Development $26.72M $10.17M
YoY Change 162.72% 80.13%
% of Gross Profit
Depreciation & Amortization $19.00K $10.00K
YoY Change 90.0% -50.0%
% of Gross Profit
Operating Expenses $34.72M $15.03M
YoY Change 131.0% 114.72%
Operating Profit -$34.72M -$15.03M
YoY Change 131.0% 114.72%
Interest Expense $948.0K $1.000K
YoY Change 94700.0%
% of Operating Profit
Other Income/Expense, Net $364.0K $457.0K
YoY Change -20.35% -108.64%
Pretax Income -$34.35M -$14.57M
YoY Change 135.77% 18.55%
Income Tax
% Of Pretax Income
Net Earnings -$34.35M -$14.57M
YoY Change 135.75% 18.59%
Net Earnings / Revenue
Basic Earnings Per Share -$0.95 -$0.41
Diluted Earnings Per Share -$0.95 -$0.41
COMMON SHARES
Basic Shares Outstanding 36.18M shares 35.91M shares
Diluted Shares Outstanding 36.18M shares 35.91M shares

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $263.5M $204.5M
YoY Change 28.84% 416.39%
Cash & Equivalents $37.32M $63.98M
Short-Term Investments $226.1M $140.5M
Other Short-Term Assets $7.477M $3.800M
YoY Change 96.76% 1166.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $270.9M $208.2M
YoY Change 30.11% 420.61%
LONG-TERM ASSETS
Property, Plant & Equipment $2.433M $166.0K
YoY Change 1365.66% 66.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $140.5M
YoY Change
Other Assets $98.00K $80.00K
YoY Change 22.5% -20.0%
Total Long-Term Assets $16.94M $141.2M
YoY Change -88.01% 70502.5%
TOTAL ASSETS
Total Short-Term Assets $270.9M $208.2M
Total Long-Term Assets $16.94M $141.2M
Total Assets $287.9M $349.5M
YoY Change -17.62% 769.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.030M $45.00K
YoY Change 11077.78% -93.57%
Accrued Expenses $18.46M $6.079M
YoY Change 203.6% 659.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.49M $6.139M
YoY Change 282.57% 309.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $13.38M $200.0K
YoY Change 6588.0% -97.85%
Total Long-Term Liabilities $13.38M $200.0K
YoY Change 6588.0% -97.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.49M $6.139M
Total Long-Term Liabilities $13.38M $200.0K
Total Liabilities $36.86M $6.325M
YoY Change 482.8% -41.44%
SHAREHOLDERS EQUITY
Retained Earnings -$182.9M -$77.69M
YoY Change 135.4%
Common Stock $5.000K $5.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $251.0M $343.1M
YoY Change
Total Liabilities & Shareholders Equity $287.9M $349.5M
YoY Change -17.62% 769.28%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$34.35M -$14.57M
YoY Change 135.75% 18.59%
Depreciation, Depletion And Amortization $19.00K $10.00K
YoY Change 90.0% -50.0%
Cash From Operating Activities -$25.16M -$13.57M
YoY Change 85.41% 171.4%
INVESTING ACTIVITIES
Capital Expenditures -$848.0K -$30.00K
YoY Change 2726.67%
Acquisitions
YoY Change
Other Investing Activities $49.05M -$279.6M
YoY Change -117.54%
Cash From Investing Activities $48.20M -$279.6M
YoY Change -117.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 185.0K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -25.16M -13.57M
Cash From Investing Activities 48.20M -279.6M
Cash From Financing Activities 185.0K 0.000
Net Change In Cash 23.23M -293.2M
YoY Change -107.92% 5683.23%
FREE CASH FLOW
Cash From Operating Activities -$25.16M -$13.57M
Capital Expenditures -$848.0K -$30.00K
Free Cash Flow -$24.31M -$13.54M
YoY Change 79.56% 170.8%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Central Index Key
EntityCentralIndexKey
0001701541
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38501
dei Entity Registrant Name
EntityRegistrantName
BLACK DIAMOND THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-4254660
dei Entity Address Address Line1
EntityAddressAddressLine1
One Main Street, 10th Floor
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34605000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
226146000 USD
dei City Area Code
CityAreaCode
(617)
dei Local Phone Number
LocalPhoneNumber
252-0848
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001
dei Trading Symbol
TradingSymbol
BDTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36213654 shares
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37324000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
280462000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7477000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4487000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
270947000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
319554000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2433000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
385000 USD
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1223000 USD
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1223000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13181000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8402000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
98000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
106000 USD
CY2021Q2 us-gaap Assets
Assets
287882000 USD
CY2020Q4 us-gaap Assets
Assets
329670000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5030000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2538000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18456000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11680000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
23486000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14218000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13376000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7694000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
36862000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
21912000 USD
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36205826 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36205826 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36078383 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36078383 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
5000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
5000 USD
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
433680000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
425363000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
211000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
614000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-182876000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-118224000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
251020000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
307758000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
287882000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
329670000 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26719000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10170000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49539000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17524000 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7996000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4858000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15889000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10383000 USD
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
34715000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
15028000 USD
us-gaap Operating Expenses
OperatingExpenses
65428000 USD
us-gaap Operating Expenses
OperatingExpenses
27907000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-34715000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15028000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-65428000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-27907000 USD
us-gaap Interest Expense
InterestExpense
0 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
1000 USD
us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
1000 USD
CY2021Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
948000 USD
CY2020Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
881000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2100000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1625000 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-584000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-423000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1324000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-433000 USD
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
364000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
457000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
776000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1191000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-34351000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-14571000 USD
us-gaap Net Income Loss
NetIncomeLoss
-64652000 USD
us-gaap Net Income Loss
NetIncomeLoss
-26716000 USD
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.95
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.95
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29804987 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36182541 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36182541 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35910718 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35910718 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36152942 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36152942 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29804987 shares
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-34351000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-14571000 USD
us-gaap Net Income Loss
NetIncomeLoss
-64652000 USD
us-gaap Net Income Loss
NetIncomeLoss
-26716000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-124000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
1012000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-403000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
1012000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34475000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13559000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65055000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25704000 USD
us-gaap Net Income Loss
NetIncomeLoss
-64652000 USD
us-gaap Net Income Loss
NetIncomeLoss
-26716000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
7652000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3296000 USD
us-gaap Depreciation
Depreciation
39000 USD
us-gaap Depreciation
Depreciation
23000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-1326000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
400000 USD
bdtx Rent Expense
RentExpense
748000 USD
bdtx Rent Expense
RentExpense
94000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
14000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2956000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2708000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-8000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
21000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1635000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1359000 USD
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
0 USD
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
15000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
7355000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2994000 USD
bdtx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-761000 USD
bdtx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-104000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-49620000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24886000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
888000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
95138000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
0 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
42576000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
279615000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
51674000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-279640000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
665000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1275000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
213844000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
665000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
213844000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2719000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-90682000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35828000 USD
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
55000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154721000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38547000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64039000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37324000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63984000 USD
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1223000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38547000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64039000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1199000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
200573000 USD
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
0 USD
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
16000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5717000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
bdtx Right Of Use Asset Derecognized Termination Of Lease
RightOfUseAssetDerecognizedTerminationOfLease
0 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-47157000 USD
bdtx Right Of Use Asset Derecognized Termination Of Lease
RightOfUseAssetDerecognizedTerminationOfLease
476000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
200573000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
212101000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
16000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1877000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-12145000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
355265000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1419000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
1012000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-14571000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
343125000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
307758000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
481000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3094000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
251020000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-279000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-30301000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
280753000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
184000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4558000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-124000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-34351000 USD
CY2020Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
3.01581
us-gaap Use Of Estimates
UseOfEstimates
Use of estimates The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
225935000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
344000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
133000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
226146000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
279848000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
651000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
37000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
280462000 USD
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0 USD
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2636000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
549000 USD
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
203000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
164000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2433000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
385000 USD
us-gaap Depreciation
Depreciation
39000 USD
us-gaap Depreciation
Depreciation
23000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
482000 USD
CY2021Q2 bdtx Accrued Contract Research Service Fees Current
AccruedContractResearchServiceFeesCurrent
11472000 USD
CY2020Q4 bdtx Accrued Contract Research Service Fees Current
AccruedContractResearchServiceFeesCurrent
5102000 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3460000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3729000 USD
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2383000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1603000 USD
CY2021Q2 bdtx Accrued Legal Fees Current
AccruedLegalFeesCurrent
659000 USD
CY2020Q4 bdtx Accrued Legal Fees Current
AccruedLegalFeesCurrent
199000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1047000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18456000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11680000 USD
CY2020Q1 bdtx Shares Authorized
SharesAuthorized
510000000 shares
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4558000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1419000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7652000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3296000 USD
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4558000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1419000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7652000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3296000 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3752744 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.71
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
62842000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1623094 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
24.66
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
110621 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
55473 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
26.62
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5209744 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M24D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8002000 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5209744 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
18.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y10M24D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
8002000 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1226756 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.39
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M18D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3671000 USD
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
46566000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-34351000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-14571000 USD
us-gaap Net Income Loss
NetIncomeLoss
-64652000 USD
us-gaap Net Income Loss
NetIncomeLoss
-26716000 USD
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36182541 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36182541 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35910718 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35910718 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36152942 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36152942 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29804987 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29804987 shares
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.95
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.95
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5274448 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3251119 shares
bdtx Lessee Operating Lease Number Of Contracts
LesseeOperatingLeaseNumberOfContracts
2 contract
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
5000 USD
CY2021Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
220000 USD
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
613000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
1075000 USD
CY2021Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
288000 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
575000 USD
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
43000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
76000 USD
CY2021Q2 us-gaap Lease Cost
LeaseCost
944000 USD
us-gaap Lease Cost
LeaseCost
1726000 USD
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
5000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
732000 USD
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y1M6D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.053
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
565000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1055000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2356000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2415000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2476000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2538000 USD
CY2021Q2 bdtx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
7073000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17913000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3045000 USD
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
14868000 USD
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
267000 USD
CY2020Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
118000 USD
CY2021Q2 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
0 USD
CY2020Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
0 USD
CY2020Q2 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
223000 USD
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
2103000 USD
CY2021Q2 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
0 USD
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
0 USD

Files In Submission

Name View Source Status
0001701541-21-000034-index-headers.html Edgar Link pending
0001701541-21-000034-index.html Edgar Link pending
0001701541-21-000034.txt Edgar Link pending
0001701541-21-000034-xbrl.zip Edgar Link pending
bdtx-20210630.htm Edgar Link pending
bdtx-20210630.xsd Edgar Link pending
bdtx-20210630_cal.xml Edgar Link unprocessable
bdtx-20210630_def.xml Edgar Link unprocessable
bdtx-20210630_htm.xml Edgar Link completed
bdtx-20210630_lab.xml Edgar Link unprocessable
bdtx-20210630_pre.xml Edgar Link unprocessable
exhibit101_q22021.htm Edgar Link pending
exhibit311_q22021.htm Edgar Link pending
exhibit312_q22021.htm Edgar Link pending
exhibit321_q22021.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending